MRNA · NASDAQ
Moderna, Inc.
$201.40 -0.88 (-0.43%)
Company overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, endemic HCoV, and hMPV+PIV3 vaccines. Its latent vaccines comprise cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines. Its public health vaccines consist of Zika and Nipah vaccines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $80.4B
- Employees
- 5,800
- Headquarters
- Cambridge, MA
- Website
- modernatx.com
- CEO
- Stéphane Bancel
- Listed
- December 7, 2018
- P/E
- -24.71
- Dividend yield
- 0.00%
Company financials
- Revenue
- $2.2B
- Gross profit
- -$309M
- Operating income
- -$3.4B
- EBITDA
- -$3B
- Net income
- -$3.2B
- EPS
- -$8.15
- Total assets
- $11.5B
- Total debt
- $1.3B
- Gross margin
- -13.89%
- Net margin
- -143.55%
- Earnings yield
- -4.05%
Showing FY 2025
MRNA
1D
NASDAQ
O240.13H241.26L180.80C202.63-43.18 (-17.57%)Vol49.95M